MK0524 Seasonal Allergic Rhinitis Study

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: September 19, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted

To assess the efficacy of MK0524 on seasonal allergies.

Condition Intervention Phase
Seasonal Allergies
Drug: MK0524
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: December 2003
Study Completion Date: December 2003

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Person has had at least 2 years of seasonal allergies
  • Person has had a positive skin test to at least 1 of the allergens of the season
  • Person is a non-smoker

Exclusion Criteria:

  • Person has been hospitalized within the last 4 weeks
  • Person is a female who has had a baby within the last 8 weeks or is still breast-feeding
  Contacts and Locations
Please refer to this study by its identifier: NCT00533208

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided by Merck Sharp & Dohme Corp.

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00533208     History of Changes
Other Study ID Numbers: 2007_616
Study First Received: September 19, 2007
Last Updated: September 19, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Rhinitis, Allergic, Seasonal
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Immune System Diseases processed this record on April 17, 2014